"Aripiprazole" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antipsychotic agent that is structurally related to piperazines and quinolones. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A.
| Descriptor ID |
D000068180
|
| MeSH Number(s) |
D03.383.606.170 D03.633.100.810.835.122
|
| Concept/Terms |
Aripiprazole- Aripiprazole
- 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone
- Aripiprazol
|
Below are MeSH descriptors whose meaning is more general than "Aripiprazole".
Below are MeSH descriptors whose meaning is more specific than "Aripiprazole".
This graph shows the total number of publications written about "Aripiprazole" by people in this website by year, and whether "Aripiprazole" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 12 | 5 | 17 |
| 2018 | 8 | 3 | 11 |
| 2019 | 5 | 1 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Aripiprazole" by people in Profiles.
-
New-onset psychosis: A case report of brief psychosis related to COVID-19 infection. Psychiatry Res. 2021 07; 301:113975.
-
Joy Journal: A Behavioral Activation Technique Used in the Treatment of Late-Life Depression Associated With Hopelessness During the COVID-19 Pandemic. Prim Care Companion CNS Disord. 2021 01 07; 23(1).
-
An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. J Psychopharmacol. 2019 10; 33(10):1227-1236.
-
Updates in treating comorbid bipolar disorder and obsessive-compulsive disorder: A systematic review. J Affect Disord. 2019 09 01; 256:433-440.
-
Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial. J Am Acad Child Adolesc Psychiatry. 2019 11; 58(11):1062-1078.
-
Aripiprazole-induced persistent hiccup: a case report and review of the literature. Psychiatr Danub. 2019 Mar; 31(1):26-31.
-
Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study. Psychiatry Res. 2019 04; 274:176-181.
-
Aripiprazole augmentation in treating comorbid bipolar disorder and obsessive-compulsive disorder: A systematic review. J Affect Disord. 2019 Apr 15; 249:15-19.
-
Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone. Int J Neuropsychopharmacol. 2018 12 01; 21(12):1090-1101.
-
Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting. J Child Adolesc Psychopharmacol. 2019 03; 29(2):133-140.